Amersham names Health President Peter Loescher as COO

TriMed Staff | | Health Imaging | Artificial Intelligence
Amersham plc has chosen Peter Loescher as COO, effective Jan. 1, 2004.

 Loescher joined Amersham in December 2002 as president of Amersham Health. In the new post, Loescher will report to Amersham Chief Executive Sir William Castell.

 Prior to joining Amersham, Loescher served as chairman and CEO of Japanese pharmaceutical firm Aventis Pharma.

TriMed Staff

Related Content

Experts highlight 'significant concerns' with fluctuating accuracy of popular large language models
FDA clears AI screening tool for cardiac amyloidosis
Are providers too trusting of AI's advice?
Pairing an alert system with CAD software halves time-to-treatment for pneumothorax
Deep learning reconstruction cuts radiation and contrast dose by half in aortic CTA exams
New study highlights the need to include more challenging datasets in AI training

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.